Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial.
Goodall RL, Meredith SK, Nunn AJ, Bayissa A, Bhatnagar AK, Bronson G, Chiang CY, Conradie F, Gurumurthy M, Kirenga B, Kiria N, Meressa D, Moodliar R, Narendran G, Ngubane N, Rassool M, Sanders K, Solanki R, Squire SB, Torrea G, Tsogt B, Tudor E, Van Deun A, Rusen ID; STREAM study collaborators. Goodall RL, et al. Among authors: bhatnagar ak. Lancet. 2022 Nov 26;400(10366):1858-1868. doi: 10.1016/S0140-6736(22)02078-5. Epub 2022 Nov 8. Lancet. 2022. PMID: 36368336 Free PMC article. Clinical Trial.
Strengthened capacity of India´s bedaquiline Conditional Access Programme for introducing new drugs and regimens.
Sachdeva KS, Arora N, Solanki R, Singla R, Sarin R, Bhatnagar A, Khanna A, Atahavale A, Shridhar R, Barua SR, Parmar M, Farooq SI, Ramachandran R, Alavadi U, Swamickan R, Tonsing J, Patel Y, Singla N. Sachdeva KS, et al. Int J Tuberc Lung Dis. 2020 Oct 1;24(10):1067-1072. doi: 10.5588/ijtld.20.0136. Int J Tuberc Lung Dis. 2020. PMID: 33126941
Validation of an indigenous assay for rapid molecular detection of rifampicin resistance in presumptive multidrug-resistant pulmonary tuberculosis patients.
Gomathi NS, Singh M, Myneedu VP, Chauhan DS, Tripathy S, Sarin R, Mohan A, Bhatnagar A, Khangembam JS, Kannan T, V Rao MV, Logani J, Dey B, Gangakhedkar RR, Swaminathan S, Singh UB. Gomathi NS, et al. Indian J Med Res. 2020 Nov;152(5):482-489. doi: 10.4103/ijmr.IJMR_2557_19. Indian J Med Res. 2020. PMID: 33707390 Free PMC article.
Pre-conference workshop on drug resistant TB - NATCON 2020.
Singla R, Chadha SS, Bhatnagar A, Solanki R, Khanna A. Singla R, et al. Indian J Tuberc. 2021 Oct;68(4):428-430. doi: 10.1016/j.ijtb.2021.02.016. Epub 2021 Mar 4. Indian J Tuberc. 2021. PMID: 34752308 Review.
Bedaquiline, Delamanid, Linezolid and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis.
Padmapriyadarsini C, Vohra V, Bhatnagar A, Solanki R, Sridhar R, Anande L, Muthuvijaylakshmi M, Bhatia M, Jeyadeepa B, Taneja G, Balaji S, Shah P, Saravanan N, Chauhan V, Kumar H, Ponnuraja C, Livchits V, Bahl M, Alavadi U, Sachdeva KS, Swaminathan S; for BEAT India Team. Padmapriyadarsini C, et al. Clin Infect Dis. 2022 Jun 29;76(3):e938-46. doi: 10.1093/cid/ciac528. Online ahead of print. Clin Infect Dis. 2022. PMID: 35767251 Free PMC article.
Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a randomised controlled trial.
Rosu L, Madan JJ, Tomeny EM, Muniyandi M, Nidoi J, Girma M, Vilc V, Bindroo P, Dhandhukiya R, Bayissa AK, Meressa D, Narendran G, Solanki R, Bhatnagar AK, Tudor E, Kirenga B, Meredith SK, Nunn AJ, Bronson G, Rusen ID, Squire SB, Worrall E; STREAM Study Health Economic Evaluation Collaborators. Rosu L, et al. Among authors: bhatnagar ak. Lancet Glob Health. 2023 Feb;11(2):e265-e277. doi: 10.1016/S2214-109X(22)00498-3. Epub 2022 Dec 21. Lancet Glob Health. 2023. PMID: 36565704 Free article. Clinical Trial.
69 results